Glaukos Reports Strong 41% Revenue Growth to $150.6M, But Q1 EPS Hits $(0.34) Amid Widening Loss
GKOS sits 73% above its 52-week low of $73.16.
Summary
Glaukos Corp reported mixed first-quarter 2026 results, with net sales surging 41% year-over-year to $150.6 million, driven by strong iDose TR volume and the commercial launch of Epioxa. This robust revenue growth was previously highlighted, but the full 10-Q summary reveals a widening net loss of $19.8 million and diluted EPS of $(0.34), compared to a loss of $18.1 million and EPS of $(0.32) in the prior year. The increased loss is attributed to significant investments in operational scale-up, including an $80 million capital expenditure for a new manufacturing facility and higher SG&A and R&D spending. While the strong top-line growth is positive, the continued unprofitability and increased spending will be a key focus for investors. Traders will be watching for signs that these investments translate into improved profitability and sustained growth in future quarters.
At the time of this announcement, GKOS was trading at $126.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $73.16 to $130.23. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.